MENU

HRMY Stock Harmony Biosciences Holdings (HRMY, $29.71) entered Downtrend as Momentum indicator drops below 0 level on Jun 04, 2024

A.I.dvisor
at Tickeron.com
06/05/24
Loading...
HRMY - Harmony Biosciences Holdings
Momentum signal
Bearish Trend
Odds of DOWN Trend
Tickeron
Momentum signal
Price: $29.71
Daily change: -$0.27 (-0.9%)
Daily volume: 212.1K
Capitalization: $1.7B
Industry: Biotechnology
This indicator may be signaling that HRMY's price has further to drop, since it fell below its price logged 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options. A.I.dvisor backtested 68 similar cases where HRMY's Momentum Indicator fell below the 0 level, and of them led to a successful outcome. Odds of Success:

HRMY's RSI Indicator leaves overbought zone

The 10-day RSI Indicator for HRMY moved out of overbought territory on October 30, 2024. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

HRMY moved below its 50-day moving average on October 30, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HRMY broke above its upper Bollinger Band on October 29, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 54 cases where HRMY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 13, 2024. You may want to consider a long position or call options on HRMY as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for HRMY just turned positive on November 08, 2024. Looking at past instances where HRMY's MACD turned positive, the stock continued to rise in of 35 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HRMY advanced for three days, in of 226 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HRMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.235) is normal, around the industry mean (14.905). P/E Ratio (16.043) is within average values for comparable stocks, (98.894). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.944). HRMY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (2.880) is also within normal values, averaging (217.940).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
HRMY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
630 West Germantown Pike
Phone
+1 484 539-9800
Employees
246
Web
https://www.harmonybiosciences.com